RxDoctor Payments Data

John Wright

Optometrist · The Woodlands, TXNPI 1417970047

Payments from drug & device makers

$3,491in general payments, 2019–2025

Across 109 payments — averaging $32.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$565
  • Glaukos Corporation$478
  • Alcon$378
  • Johnson & Johnson Vision Care, Inc.$353
  • Optos, Inc.$298
  • Sun Pharmaceutical Industries Inc.$248
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$3,19291%
  • Entertainment$2989%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,491 in reported general payments places this provider in the 85th percentile of 4,315 optometrist providers in Texas.

See all optometrist providers in Texas

Medicare billing

Part B allowed, 2024
$294,638
Medicare patients
910
Services billed
4,037

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate38$50,104
RestasisCyclosporine42$37,383
XiidraLifitegrast30$34,807
VyzultaLatanoprostene Bunod69$28,568
LumiganBimatoprost33$15,847
Fluorometholone166$9,842
Cyclosporine15$9,080
Latanoprost446$5,337
Brinzolamide24$4,093
Travoprost26$3,574
Loteprednol Etabonate29$3,304
Tobramycin-DexamethasoneTobramycin/Dexamethasone72$3,229
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat141$2,382
Timolol Maleate195$1,646
Prednisolone Acetate25$937

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$565$63,37599 claims
AbbVieRestasis, Lumigan$102$53,23075 claims
Oyster Point Pharma, Inc.Tyrvaya$115$50,10438 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$178$3,30429 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,315 optometrist providers in Texas.

Other optometrist in The Woodlands

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →